D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine

被引:15
|
作者
Kimura, Shun-ichi [1 ]
Wada, Hidenori [1 ]
Ishihara, Yuko [1 ]
Kawamura, Koji [1 ]
Sakamoto, Kana [1 ]
Yamasaki, Ryoko [1 ]
Ashizawa, Masahiro [1 ]
Machishima, Tomohito [1 ]
Sato, Miki [1 ]
Terasako, Kiriko [1 ]
Nakasone, Hideki [1 ]
Kikuchi, Misato [1 ]
Okuda, Shinya [1 ]
Kako, Shinichi [1 ]
Kanda, Junya [1 ]
Yamazaki, Rie [1 ]
Tanihara, Aki [1 ]
Nishida, Junji [1 ]
Kanda, Yoshinobu [1 ]
机构
[1] Jichi Med Univ, Saitama Med Ctr, Div Hematol, Saitama 3308503, Japan
关键词
Neutropenia; D-index; Pulmonary infection; Acute myeloid leukemia; High-dose cytarabine; INVASIVE FUNGAL DISEASE; NEUTROPENIC PATIENTS; HIGH-RISK; CURVE; AREA;
D O I
10.1179/1607845413Y.0000000103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The D-index is calculated as the area over the neutrophil curve during neutropenia. We investigated the impact of the D-index on pulmonary infection in 33 acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. There was no difference in the D-index between chemotherapies with and without pulmonary infection. The cumulative D-index (c-D-index) until the development of infection exceeded 4000 in four of five patients with pulmonary infection. Although there was no difference in the total D-index throughout the overall consolidation chemotherapy, the total D-index from induction to consolidation and the D-index at induction chemotherapy were higher in patients with pulmonary infection during consolidation than in those without it (P = 0.014 and 0.019, respectively). Our results showed that the cumulative effect of neutropenia might determine the risk of pulmonary infection in consolidation chemotherapy. We are planning a clinical trial of c-D-index-guided preemptive antifungal therapy.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 50 条
  • [21] High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
    R F Schlenk
    U Germing
    F Hartmann
    A Glasmacher
    J T Fischer
    F del Valle y Fuentes
    K Götze
    H Pralle
    C Nerl
    H Salwender
    W Grimminger
    A Petzer
    M Hensel
    A Benner
    L Zick
    K Döhner
    S Fröhling
    H Döhner
    Leukemia, 2005, 19 : 978 - 983
  • [22] High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
    Schlenk, RF
    Germing, U
    Hartmann, F
    Glasmacher, A
    Fischer, JT
    Fuentes, FDY
    Götze, K
    Pralle, H
    Nerl, C
    Salwender, H
    Grimminger, W
    Petzer, A
    Hensel, M
    Benner, A
    Zick, L
    Döhner, K
    Fröhling, S
    Döhner, H
    LEUKEMIA, 2005, 19 (06) : 978 - 983
  • [23] Safety and feasibility of outpatient high-dose cytarabine (HIDAC) and intermediate-dose cytarabine (IDAC) for consolidation therapy in acute myeloid leukemia (AML).
    Li, Wenhui
    Simondsen, Katherine
    Lee, Jamie
    Elharake, Maher
    Kubal, Timothy Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Results of high-dose cytarabine consolidation and interferon alpha maintenance therapy in acute myeloid leukemia (AML)
    Saikia, TK
    Advani, SH
    Gopal, R
    Nair, CN
    Sawant, VS
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 226 - 226
  • [25] Antimicrobial prophylaxis during high dose cytarabine consolidation in acute myeloid leukemia
    Ingham, Randall
    Cardin, Michael
    Reagan, John Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
    Bishop, JF
    Matthews, JP
    Young, GA
    Szer, J
    Gillett, A
    Joshua, D
    Bradstock, K
    Enno, A
    Wolf, MM
    Fox, R
    Cobcroft, R
    Herrmann, R
    VanDerWeyden, M
    Lowenthal, RM
    Page, F
    Garson, OM
    Juneja, S
    BLOOD, 1996, 87 (05) : 1710 - 1717
  • [27] Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients
    Tangchitpianvit, Kittisak
    Rattarittamrong, Ekarat
    Chai-Adisaksopha, Chatree
    Piriyakhuntorn, Pokpong
    Rattanathammethee, Thanawat
    Hantrakool, Sasinee
    Tantiworawit, Adisak
    Norasetthada, Lalita
    HEMATOLOGY, 2021, 26 (01) : 355 - 364
  • [28] MITOZANTRONE AND HIGH-DOSE CYTARABINE IN ADULT ACUTE MYELOID-LEUKEMIA
    MARCUS, RE
    CATOVSKY, D
    GOLDMAN, JM
    GALTON, DAG
    NEWLAND, AC
    SLOCOMBE, G
    HEGDE, U
    LANCET, 1985, 1 (8442): : 1384 - 1384
  • [29] Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia
    Deisseroth, Albert
    Farrell, Ann
    Justice, Robert
    Kane, Robert
    Sridhara, Rajeshwari
    Chen, Huanyu
    He, Kun
    Pazdur, Richard
    BLOOD, 2010, 115 (02) : 430 - 430
  • [30] Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy
    Canaani, Jonathan
    Luskin, Marlise R.
    Loren, Alison
    Timlin, Colleen
    Mangan, James
    Hexner, Elizabeth O.
    Frey, Noelle V.
    Porter, David L.
    Stadtmauer, Edward A.
    Luger, Selina
    BLOOD, 2015, 126 (23)